Clinical research study| Volume 125, ISSUE 4, P381-393, April 2012

Download started.


Evaluation of Harm in the Pharmacotherapy of Irritable Bowel Syndrome



      Current treatment options for irritable bowel syndrome are limited and often poorly studied. A select few drugs have been studied in irritable bowel syndrome, and the number needed to treat is frequently used to assess the relative efficacy of these treatments. However, side effects are an important consideration in the clinical decision on which particular treatment to use. This study examines trials of subjects with irritable bowel syndrome with diarrhea and constipation who are receiving a drug intervention deemed of merit by the American College of Gastroenterology task force and compares these therapies to examine the number needed to harm using a systematic review and meta-analysis approach.


      Potential studies of irritable bowel syndrome treatments were identified through a search of MEDLINE (1950 to April 2011), EMBASE (1980 to April 2011), the Cochrane central register of controlled trials, and the bibliography of recent meta-analyses. Clinical trials of pharmacotherapy for irritable bowel syndrome were eligible for inclusion only if a description of adverse events and the number of patients who discontinued treatment because of adverse events were reported. The relative risk of experiencing an adverse event requiring discontinuation of treatment was used to determine the number needed to harm. In addition, the number and severity of adverse events were summarized.


      Twenty-six clinical trials (4 with selective serotonin reuptake inhibitors, 3 with lubiprostone, 6 with tricyclic antidepressants, 8 with alosetron, and 5 with rifaximin) were included. Lubiprostone was safe with insignificant harm in one combined phase III trial. Selective serotonin reuptake inhibitors did not have enough data for a reliable meta-analysis of harm but seemed to be safe. More rigorous data were available for tricyclic antidepressants, alosetron, and rifaximin; the numbers needed to harm were 18.3, 19.4, and 8971, respectively, and the numbers needed to treat were 8, 7.5, and 10.6, respectively. For tricyclic antidepressant and alosetron, an adverse event resulting in discontinuation of the study medication occurred for every 2.3 and 2.6 patients who benefited from a drug, respectively. For rifaximin, this number was 846 patients. In addition, adverse events were more common with tricyclic antidepressants and alosetron.


      In irritable bowel syndrome with diarrhea, tricyclic antidepressants and alosetron are associated with a significant number needed to harm compared with rifaximin. Apart from lubiprostone, treatment of irritable bowel syndrome with constipation is limited to small studies (with poor descriptions of side effects), although lubiprostone and selective serotonin reuptake inhibitors appear safe.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Saito Y.A.
        • Schoenfeld P.
        • Locke 3rd., G.R.
        The epidemiology of irritable bowel syndrome in North America: a systematic review.
        Am J Gastroenterol. 2002; 97: 1910-1915
        • Longstreth G.F.
        Definition and classification of irritable bowel syndrome: current consensus and controversies.
        Gastroenterol Clin N. 2005; 34: 173-187
        • Ersryd A.
        • Posserud I.
        • Abrahamsson H.
        • et al.
        Subtyping the irritable bowel syndrome by predominant bowel habit: Rome II versus Rome III.
        Aliment Pharmacol Ther. 2007; 26: 953-961
        • Heaton K.W.
        • O'Donnell L.J.
        An office guide to whole-gut transit time.
        J Clin Gastroenterol. 1994; 19: 28-30
        • Longstreth G.F.
        • Thompson W.G.
        • Chey W.D.
        • et al.
        Functional bowel disorders.
        Gastroenterology. 2006; 130: 1480-1491
        • Delvaux M.
        Role of visceral sensitivity in the pathophysiology of irritable bowel syndrome.
        Gut. 2002; 51: 67-71
        • Camilleri M.
        Serotonin in the gastrointestinal tract.
        Curr Opin Endocrinol Diabetes Obes. 2009; 16: 53-59
        • Collins S.M.
        • Denou E.
        • Verdu E.F.
        • et al.
        The putative role of the intestinal microbiota in irritable bowel syndrome.
        Digest Liver Dis. 2009; 41: 850-853
        • Brandt L.J.
        • Chey W.D.
        • et al.
        • American College of Gastroenterology Task Force on Irritable Bowel Syndrome
        An evidence-based position statement on the management of irritable bowel syndrome.
        Am J Gastroenterol. 2009; 104: S1-S35
        • Ford A.C.
        • Brandt L.J.
        • Young C.
        • et al.
        Efficacy of 5-HT 3 antagonists and 5-HT 4 agonists in irritable bowel syndrome: systematic review and meta-analysis.
        Am J Gastroenterol. 2009; 104: 1831-1843
        • Ford A.C.
        • Talley N.J.
        • Schoenfeld P.S.
        • et al.
        Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis.
        Gut. 2009; 58: 367-378
        • Menees S.B.
        • Maneerattanaporn M.
        • Chey W.D.
        Efficacy of rifaximin in patients with irritable bowel syndrome: a meta analysis.
        Gastroenterology. 2011; 215: A54
        • Spiegel B.M.
        Questioning the bacterial overgrowth hypothesis of IBS: an epidemiologic and evolutionary perspective.
        Clin Gastroenterol H. 2011 Mar 10; ([Epub ahead of print])
        • Moher D.
        • Liberati A.
        • Tetzlaff J.
        • et al.
        Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement.
        Ann Intern Med. 2009; 151: 264-269
        • DerSimonian R.
        • Laird N.
        Meta-analysis in clinical trials.
        Control Clin Trials. 1986; 7: 177-188
        • Hulley S.B.
        • Cummings S.R.
        • Browner W.S.
        • et al.
        Designing Clinical Research.
        in: Seigafuse S. Winter N. Utilizing Existing Databases. 3rd ed. Lippincott, Williams, & Wilkins, Philadelphia, PA2007: 220
        • Sweeting M.J.
        • Sutton A.J.
        • Lambert P.C.
        What to add to nothing?.
        Stat Med. 2004; 23: 1351-1375
        • Harbord R.M.
        • Egger M.
        • Sterne J.A.C.
        A modified test for small-study effects in meta-analysis of controlled clinical trials with binary endpoints.
        Stat Med. 2006; 25: 3443-3457
        • Boerner D.
        • Eberhardt R.
        • Metz K.
        • et al.
        Wirksamkeit und vertraglichkeit eines antidepressivuns beim colon irritabile.
        Therapiewoche. 1988; 38: 201-208
        • Bergmann M.
        • Heddergott A.
        • Schlosser T.
        Die therapie des colon irritabile mit trimipramin (Herphonal) - Eine kontrollierte studie.
        Z Klin Med. 1991; 46: 1621-1628
        • Drossman D.A.
        • Toner B.B.
        • Whitehead W.E.
        • et al.
        Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders.
        Gastroenterology. 2003; 125: 19-31
        • Heefner J.D.
        • Wilder R.M.
        • Wilson I.D.
        Irritable colon and depression.
        Psychosomatics. 1978; 19: 540-547
        • Myren J.
        • Groth H.
        • Larssen S.E.
        • et al.
        The effect of trimipramine in patients with the irritable bowel syndrome: a double-blind study.
        Scand J Gastroenterol. 1982; 17: 871-875
        • Nigam P.
        • Kapoor K.K.
        • Rastog C.K.
        • et al.
        Different therapeutic regimens in irritable bowel syndrome.
        J Assoc Physicians India. 1984; 32: 1041-1044
        • Talley N.J.
        • Kellow J.E.
        • Boyce P.
        • et al.
        Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial.
        Digest Dis Sci. 2008; 53: 108-115
        • Vahedi H.
        • Merat S.
        • Momtahen S.
        • et al.
        Clinical trial: the effect of amitriptyline in patients with diarrhea-predominant irritable bowel syndrome.
        Aliment Pharmacol Ther. 2008; 27: 678-684
        • Vij J.C.
        • Jiloha R.C.
        • Kumar N.
        • et al.
        Effect of antidepressant drug (doxepin) on irritable bowel syndrome patients.
        Indian J Psychiatry. 1991; 33: 243-246
        • Bardhan K.D.
        • Bodemar G.
        • Geldof H.
        • et al.
        A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome.
        Aliment Pharmacol Ther. 2000; 14: 23-34
        • Camilleri M.
        • Mayer E.A.
        • Drossman D.A.
        • et al.
        Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist.
        Aliment Pharmacol Ther. 1999; 13: 1149-1159
        • Camilleri M.
        • Northcutt A.R.
        • Kong S.
        • et al.
        Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial.
        Lancet. 2000; 355: 1035-1040
        • Camilleri M.
        • Chey W.Y.
        • Mayer E.A.
        • et al.
        A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome.
        Arch Intern Med. 2001; 161: 1733-1740
        • Chang L.
        • Ameen V.Z.
        • Dukes G.E.
        • et al.
        A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.
        Am J Gastroenterol. 2005; 100: 115-123
        • Krause R.
        • Ameen V.
        • Gordon S.H.
        • et al.
        A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.
        Am J Gastroenterol. 2007; 102: 1709-1719
        • Chey W.D.
        • Chey W.Y.
        • Heath A.T.
        • et al.
        Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome.
        Am J Gastroenterol. 2004; 99: 2195-2203
        • Lembo T.
        • Wright R.A.
        • Bagby B.
        • et al.
        • Lotronex Investigator Team
        Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome.
        Am J Gastroenterol. 2001; 96: 2662-2670
        • Sharara A.I.
        • Aoun E.
        • Abdul-Baki H.
        • et al.
        A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence.
        Am J Gastroenterol. 2006; 101: 326-333
        • Pimentel M.
        • Park S.
        • Mirocha J.
        • et al.
        The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome.
        Ann Intern Med. 2006; 145: 557-563
        • Pimentel M.
        • Lembo A.
        • Chey W.D.
        • et al.
        Rifaximin therapy for patients with irritable bowel syndrome without constipation.
        N Engl J Med. 2011; 364: 22-32
        • Lembo A.
        • Zakko S.F.
        • Ferreira N.L.
        • et al.
        Rifaximin for the treatment of diarrhea-associated irritable bowel syndrome: short term treatment leading to long term sustained response.
        Gastroenterology. 2008; 134: A545
        • Tabas G.
        • Beaves M.
        • Wang J.
        • et al.
        Paroxetine to treat irritable bowel syndrome not responding to high fiber diet: a double-blind placebo-controlled trial.
        Am J Gastroenterol. 2004; 99: 914-920
        • Tack J.
        • Broekaert D.
        • Fischler B.
        • et al.
        A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome.
        Gut. 2006; 55: 1095-1103
        • Vahedi H.
        • Merat S.
        • Rashidioon A.
        • et al.
        The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized controlled study.
        Aliment Pharmacol Ther. 2005; 22: 381-385
        • Kuiken S.D.
        • Tytgat G.N.J.
        • Boeckxstaens G.E.E.
        The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double-blind, randomized, placebo-controlled study.
        Clin Gastroenterol Hepatol. 2003; 1: 219-228
        • Johanson J.F.
        • Drossman D.A.
        • Panas R.
        • et al.
        Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation.
        Aliment Pharmacol Ther. 2008; 27: 685-696
        • Drossman D.A.
        • Chey W.D.
        • Johanson J.F.
        • et al.
        Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome—results of two randomized placebo-controlled studies.
        Aliment Pharmacol Ther. 2008; 29: 329-341
        • Agarwal N.
        • Spiegel B.M.
        The effect of irritable bowel syndrome on health-related quality of life and health care expenditure.
        Gastroenterol Clin North Am. 2011; 40: 11-19